New perspectives in the management of Pseudomonas aeruginosa infections
- PMID: 25156380
- DOI: 10.2217/fmb.14.42
New perspectives in the management of Pseudomonas aeruginosa infections
Abstract
Infections with Pseudomonas aeruginosa are a major health problem, especially for immune-compromised and cystic fibrosis patients, owing to the particular drug resistance of the microorganism. The aim of this review is to provide recent insights into strategies under investigation for prevention and therapy of these infections. In this survey, the approach directed against bacterial biofilm formation and quorum-sensing systems was focused, along with the evaluation of the treatment with bacteriophages. New interesting, developmental studies and clinical trials to prevent or treat infections due to this opportunistic pathogen are based on active and passive immunotherapy. Some monoclonal antibodies and different vaccines against this microorganism have been developed in the last few decades, even though to date none of them have obtained market authorization.
Keywords: Pseudomonas aeruginosa; bacteriophages; biofilm; cystic fibrosis; immunotherapy; nanoparticles; quorum sensing.
Similar articles
-
Novel therapeutic strategies to counter Pseudomonas aeruginosa infections.Expert Rev Anti Infect Ther. 2012 Feb;10(2):219-35. doi: 10.1586/eri.11.168. Expert Rev Anti Infect Ther. 2012. PMID: 22339195 Review.
-
Targeting quorum sensing in Pseudomonas aeruginosa biofilms: current and emerging inhibitors.Future Microbiol. 2013 Jul;8(7):901-21. doi: 10.2217/fmb.13.57. Future Microbiol. 2013. PMID: 23841636 Review.
-
Central role of quorum sensing in regulating the production of pathogenicity factors in Pseudomonas aeruginosa.Future Microbiol. 2008 Feb;3(1):97-106. doi: 10.2217/17460913.3.1.97. Future Microbiol. 2008. PMID: 18230038 Review.
-
Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients.Curr Opin Pediatr. 2007 Feb;19(1):83-8. doi: 10.1097/MOP.0b013e3280123a5d. Curr Opin Pediatr. 2007. PMID: 17224667 Review.
-
Vaccines and immunotherapy against Pseudomonas aeruginosa.Vaccine. 2008 Feb 20;26(8):1011-24. doi: 10.1016/j.vaccine.2007.12.007. Epub 2007 Dec 26. Vaccine. 2008. PMID: 18242792 Review.
Cited by
-
Pseudomonas aeruginosa: Infections and novel approaches to treatment "Knowing the enemy" the threat of Pseudomonas aeruginosa and exploring novel approaches to treatment.Infect Med (Beijing). 2023 May 26;2(3):178-194. doi: 10.1016/j.imj.2023.05.003. eCollection 2023 Sep. Infect Med (Beijing). 2023. PMID: 38073886 Free PMC article. Review.
-
Copper(ii) and silver(i) complexes with dimethyl 6-(pyrazine-2-yl)pyridine-3,4-dicarboxylate (py-2pz): the influence of the metal ion on the antimicrobial potential of the complex.RSC Adv. 2023 Feb 1;13(7):4376-4393. doi: 10.1039/d2ra07401j. eCollection 2023 Jan 31. RSC Adv. 2023. PMID: 36744286 Free PMC article.
-
The Antibacterial Effect of PEGylated Carbosilane Dendrimers on P. aeruginosa Alone and in Combination with Phage-Derived Endolysin.Int J Mol Sci. 2022 Feb 7;23(3):1873. doi: 10.3390/ijms23031873. Int J Mol Sci. 2022. PMID: 35163794 Free PMC article.
-
It's Not Easy Being Green: A Narrative Review on the Microbiology, Virulence and Therapeutic Prospects of Multidrug-Resistant Pseudomonas aeruginosa.Antibiotics (Basel). 2021 Jan 4;10(1):42. doi: 10.3390/antibiotics10010042. Antibiotics (Basel). 2021. PMID: 33406652 Free PMC article. Review.
-
The Landscape of Pseudomonas aeruginosa Membrane-Associated Proteins.Cells. 2020 Nov 5;9(11):2421. doi: 10.3390/cells9112421. Cells. 2020. PMID: 33167383 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
